What Patient Selection Criteria And Contraindications Should Medical Aesthetic Clinics Evaluate Prior To Performing Deep Ablative Co2 Or Er:yag Laser Resurfacing Procedures? Key Screening And Safety Steps

Before deep ablative CO2 or Er:YAG resurfacing, clinics should confirm that the patient can heal predictably, tolerate the risks, and follow intensive wound care. Screening should cover recent isotretinoin use, active infection, vascular and immune status, prior radiation or procedures, scarring tendency, skin phototype, eyelid support when treating periocular skin, and the patient’s expectations. Deep full-field resurfacing is most predictable in lighter skin types with intact adnexal structures and reliable postoperative care.

Deep ablative resurfacing removes substantial epidermis and part of the dermis, so safe selection depends on more than the indication. Any factor that impairs re-epithelialization, increases abnormal scarring, promotes infection, or makes postoperative care unreliable should lead to postponement, modification, or selection of a less aggressive treatment.

Determine Whether Deep Ablation Is Appropriate

Match Treatment Depth to the Clinical Problem

Deep CO2 or Er:YAG resurfacing may be appropriate for severe rhytids, pronounced photodamage, or deep atrophic scars when the expected benefit justifies prolonged healing and greater complication risk.

Milder texture concerns generally do not require the same treatment depth. Fractional, superficial, or non-ablative approaches may provide a more favorable risk-benefit balance, particularly in higher-risk patients.

Confirm Adequate Healing Capacity

The clinician should assess conditions and treatments that impair wound healing, immune response, vascular supply, or epidermal regeneration.

The evaluation should include systemic disease, immunodeficiency, autoimmune or collagen vascular disease, prior radiation, smoking, current and recent medications, and previous procedures at the proposed treatment site.

Assess Patient Reliability

Patients must understand that deep resurfacing requires intensive wound care, strict sun avoidance, follow-up, and prompt reporting of infection or delayed healing.

An inability or unwillingness to comply with postoperative instructions is a contraindication to proceeding, because preventable wound-care failures can materially increase infection, scarring, and pigmentary complications.

Screen for Contraindications

Active Infection Is a Reason to Defer Treatment

Active bacterial, viral, or fungal infection in or near the treatment area should be treated before resurfacing.

A history of herpes simplex is not usually an absolute contraindication, but it requires an appropriate oral antiviral prophylaxis plan beginning before treatment and continuing through re-epithelialization according to the treating clinician’s protocol.

Recent Oral Isotretinoin Requires Caution

Deep full-field ablative resurfacing should generally be postponed after oral isotretinoin because impaired sebaceous and adnexal function may delay re-epithelialization and increase abnormal-scarring risk.

A commonly used interval is at least 6 months, with some clinicians extending the delay to 12 months or longer for extensive or particularly deep treatments. The decision should be individualized based on treatment depth, treatment area, dose history, and current skin recovery; the older assumption that every laser procedure requires the same fixed waiting period does not apply to all fractional or non-ablative procedures.

Damaged Adnexal Structures May Prevent Normal Re-Epithelialization

Hair follicles and sebaceous glands provide cells that help restore the epidermis after ablation. Skin with absent or severely damaged appendages may therefore heal unpredictably.

Particular caution is required for areas affected by:

Prior ionizing or X-ray radiation
Burn scars
Scleroderma or significant dermal fibrosis
Previous deep peels, dermabrasion, or deep laser resurfacing
Recent extensive electrolysis that destroyed hair follicles

Deep ablation should generally be avoided on severely compromised skin unless the clinician has a compelling indication and a defensible alternative plan.

Vascular and Microvascular Disease Raises Risk

Active smoking compromises tissue oxygenation and vascularity, increasing the risk of delayed healing and tissue necrosis. Elective deep resurfacing should be deferred until smoking-related risk has been addressed.

Previous head or neck radiation and diseases such as scleroderma, systemic lupus erythematosus, or Sjögren syndrome can also impair microvascular function and wound repair. These are typically relative contraindications, but they may make deep full-field treatment inappropriate in the affected area.

Evaluate Abnormal Scarring

A personal history of keloids or hypertrophic scars increases the risk of an exaggerated scar response after ablation.

This is generally a relative rather than universal contraindication. Options may include avoiding deep treatment, using more conservative parameters, obtaining specialist input, and performing a test spot when clinically appropriate. Active or uncontrolled keloid or hypertrophic scar formation warrants deferral.

Account for Diseases With Koebner Phenomenon

Psoriasis, vitiligo, lichen planus, and similar disorders may worsen or develop new lesions after cutaneous trauma.

Active disease in the treatment area should generally prompt postponement. Even when disease is controlled, the clinician should discuss the possibility of an isomorphic response and consider a less aggressive modality.

Evaluate Skin Phototype and Pigment Risk

Fitzpatrick Type Influences the Risk Profile

Fitzpatrick skin types I and II have the lowest risk of post-inflammatory hyperpigmentation after deep ablative resurfacing. Some type III patients may also be suitable after careful assessment and counseling.

Types IV to VI have substantially greater risk of prolonged or permanent dyschromia, particularly with deep full-field treatment. Fractional or superficial approaches are often preferable, with strict photoprotection and conservative parameter selection.

Do Not Use Phototype as the Only Selection Criterion

Skin phototype is a risk marker, not a complete eligibility test. The clinician should also consider the patient’s history of hyperpigmentation, current tanning or sun exposure, prior inflammatory pigment changes, and ability to maintain sun protection.

The risk discussion should distinguish temporary postoperative erythema and pigmentation from potentially persistent dyschromia.

Assess the Periocular Area Separately

Check Eyelid Laxity and Support

Patients undergoing periocular resurfacing should be assessed for lid laxity, lower-lid position, and other factors that could increase the risk of postoperative ectropion.

Aggressive treatment of poorly supported lower eyelid skin may produce functional complications even when the laser treatment itself is technically appropriate. High-risk patients may require a modified plan, staged treatment, or evaluation by an appropriate oculoplastic specialist.

Confirm That the Treatment Area Is Healthy

The clinician should inspect for active lesions, inflammation, infection, scarring, fibrosis, and altered skin texture before treating near the eyes or elsewhere on the face.

Deep ablation should not be used to treat overlying skin whose regenerative capacity is substantially reduced without carefully reassessing the indication and expected healing course.

Resolve Expectations Before Treatment

Explain the Recovery Burden

Patients should understand that deep ablative resurfacing involves a meaningful recovery period, visible erythema, wound care, infection risk, pigmentary change, and the possibility of scarring or incomplete improvement.

The expected result should be described realistically. Resurfacing can improve texture, rhytids, and selected scars, but it does not guarantee complete correction or eliminate the need for future maintenance.

Identify Motivation and Risk Tolerance

A patient seeking an immediate, risk-free result is not an appropriate candidate for a deep ablative procedure.

The consultation should establish whether the patient accepts the recovery time, understands the possibility of suboptimal outcomes, and can make an informed decision without unrealistic expectations.

Understanding the Trade-offs

More Ablation Can Increase Both Benefit and Harm

Deeper treatment can produce greater remodeling for selected indications, but it also increases the burden of re-epithelialization and the likelihood of infection, delayed healing, scarring, erythema, and dyschromia.

The deepest available setting is therefore not automatically the best setting. Treatment depth should be the minimum necessary to address the patient’s defined problem.

CO2 and Er:YAG Are Not Interchangeable in Every Patient

Both technologies can create significant ablative injury, but their tissue effects and clinical settings differ. Patient selection should be based on the planned depth, density, full-field versus fractional delivery, anatomic site, and operator experience rather than the device label alone.

A patient who is unsuitable for deep full-field resurfacing may still be a candidate for a less aggressive fractional or non-ablative procedure.

“Relative” Does Not Mean “Low Risk”

Autoimmune disease, prior radiation, darker phototype, abnormal scarring history, and prior dermal injury may not prohibit every form of resurfacing.

They do require a documented risk-benefit assessment, modified treatment strategy, enhanced counseling, and a clear reason that the expected benefit justifies the additional risk.

Making the Right Choice for Your Goal

The final decision should be documented as a treatment-specific assessment, not simply as a device-based eligibility decision.

If your primary focus is wound-healing safety: Defer treatment for active infection, recent oral isotretinoin exposure, severely compromised adnexal skin, uncontrolled systemic risk, or inability to perform postoperative care.
If your primary focus is minimizing pigmentary complications: Favor conservative, fractional, or non-ablative treatment for darker phototypes and require rigorous pre- and postoperative photoprotection.
If your primary focus is preventing abnormal scarring: Review keloid and hypertrophic-scar history, avoid treatment during active scar formation, and consider test spots or specialist input for higher-risk patients.
If your primary focus is periocular safety: Assess eyelid laxity and support before treating near the eyes, and modify or avoid aggressive treatment when ectropion risk is substantial.
If your primary focus is predictable patient satisfaction: Proceed only when the patient understands the recovery, risks, likely degree of improvement, and limitations of deep resurfacing.

The safest candidate is one whose skin can heal predictably, whose risk factors are manageable, and whose expectations match the realities of deep ablative treatment.

Summary Table:

Criterion	Key Considerations
Healing capacity	Assess systemic diseases, immune status, recent isotretinoin, smoking, and prior procedures.
Active infection	Defer treatment; treat first. For HSV history, use prophylaxis.
Skin type	Types I-II lower risk; types IV-VI higher risk for dyschromia; consider fractional.
Abnormal scarring	History of keloids/hypertrophic scars: relative contraindication; consider test spot.
Periocular safety	Check eyelid laxity/support to prevent ectropion.
Patient expectation	Ensure realistic understanding of recovery, risks, and outcomes.

Ready to enhance your clinic's laser resurfacing protocols with expert guidance? At BELIS, we specialize in professional-grade aesthetic devices, offering a full spectrum of laser systems (CO2 Fractional, Erbium, Diode, Alexandrite, Nd:YAG, Pico) and more. Our team provides comprehensive training and support to help you achieve optimal patient outcomes. Contact us today to discuss how our advanced technology can elevate your practice and drive success.